Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).

Trial Details

NCT ID
NCT05253495
Phase
PHASE2
Sponsor
New York Medical College
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • DOC Group B
  • Pv-COMRAD 1 and 2 Group B
  • Pv-R-CYM 1 and 2 Group B
  • DOC Group C
  • MAD CPR 1 and 2
  • Pv-R CYVE 1 and 2
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Gainsville, Florida, United States
  • Vallhala, New York, United States

Key Eligibility Criteria

  • Newly diagnosed patients with histologically or cytologically proven newly diagnosed MB-NHL or cHL according to WHO Classification who meet the fol…
  • Burkitt lymphoma (ICD-O 9687/3) Burkitt-like lymphoma with 11q aberration (ICD-O 9687/3) Diffuse large B-cell lymphoma, NOS (ICD-O 9680/3) High gra…
  • COHORT Ia: stage III with LDH ≥ 2 ULN OR stage IV (5-24% bone marrow lymphoma infiltration) (GROUP B)61
  • COHORT Ib: any CNS involvement and/or BM involvement (≥ 25% lymphoma cells) (GROUP C)61 OR patients with less than 20% tumor size reduction post ch…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →